37 results
8-K
EX-10.1
ADIL
Adial Pharmaceuticals Inc
2 Jun 23
Entry into a Material Definitive Agreement
6:02am
, cost and expense (including, without limitation, reasonable attorneys’ fees and disbursements and costs and expenses of expert witnesses
8-K
EX-99.1
ADIL
Adial Pharmaceuticals Inc
6 Sep 22
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s
9:10am
by Dr. Peter Ernst, DVM, PhD, Professor of Pathology at the University of California San Diego (UC San Diego), an expert in the fields of immunology
POS AM
gyispeq3ge8i349o
24 Jun 22
Prospectus update (post-effective amendment)
5:11pm
POS AM
3n85cu4ffcpwoch8hj9
24 Jun 22
Prospectus update (post-effective amendment)
5:02pm
8-K
EX-10.1
5tmp3mf nk5us7nqk1
9 Dec 21
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer
9:29am
POS AM
ao32798nzf
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
POS AM
nt4nakqj6ix9
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
POS AM
ksgmo ve0
22 Apr 20
Prospectus update (post-effective amendment)
5:05pm
POS AM
grrhupcuxpnprc8g
22 Apr 20
Prospectus update (post-effective amendment)
5:04pm
DEF 14A
t1gm7qyw0w
8 Jul 19
Definitive proxy
4:06pm